Pharma execs and boards essentially pressed pause on dealmaking as 2016 came to a close, with uncertainties about the U.S. presidential election—and a Donald Trump presidency—holding companies back.
Readers are full of surprises. Sometimes, stories we editors put on top of the news don’t make the cut with readers. Others are unexpected hits. Still others resurface from the past. Find all three in this year's roundup of 2016 news curated by you, our readers.
Biopharma shares soared with Donald Trump's presidential victory as the threat of sweeping action against drug prices lifted. But Trump won't be idle on pricing, analysts say, and his ferocious opposition to trade deals could be a long-term headache for the decidedly global pharma business.
An email recently disclosed by WikiLeaks shows a Hillary Clinton chief strategist urged taking the pharma price issue away from Sen. Bernie Sanders with a “big, bold aggressive plan to take on this industry.”
While many pharma watchers are closely focused on the headlining presidential race this election season, a vote coming in California poses a big risk to the industry.
When a single tweet from Hillary Clinton sent biopharma shares tumbling last fall, her campaign staff gleefully declared war on pharma, according to newly released WikiLeaks emails.
Hillary Clinton is now taking a different tack against pharma. In a speech planned for Monday, Clinton will call out EpiPen maker Mylan as a “bad actor” for its huge price hikes, and propose new government measures to encourage competition and break monopoly access to markets.
With drug prices dominating attention in Congress and agitating the public, GPhA CEO Chip Davis wants to be sure that low-cost generics are top of mind as a way to save money--and he has some ideas to amp up their strength in the marketplace.
